Other
GX-03
GX-03 is an intervention with 2 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
COMBINATION PRODUCT
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
completed150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_2
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
NCT07355075
completedphase_2
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
NCT04951349
Clinical Trials (2)
Showing 2 of 2 trials
NCT07355075Phase 2
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
NCT04951349Phase 2
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
All 2 trials loaded
Drug Details
- Intervention Type
- COMBINATION PRODUCT
- Total Trials
- 2